Teva Pharmaceutical Industries (TEVA) Net Cash Flow: 2009-2025
Historic Net Cash Flow for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $51.0 million.
- Teva Pharmaceutical Industries' Net Cash Flow fell 94.69% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 197.25%. This contributed to the annual value of $248.0 million for FY2024, which is 41.37% down from last year.
- Latest data reveals that Teva Pharmaceutical Industries reported Net Cash Flow of $51.0 million as of Q3 2025, which was down 89.13% from $469.0 million recorded in Q2 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Net Cash Flow registered a high of $961.0 million during Q3 2024, and its lowest value of -$1.6 billion during Q1 2025.
- In the last 3 years, Teva Pharmaceutical Industries' Net Cash Flow had a median value of $51.0 million in 2025 and averaged -$41.5 million.
- In the last 5 years, Teva Pharmaceutical Industries' Net Cash Flow spiked by 1,686.11% in 2023 and then slumped by 1,158.02% in 2025.
- Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Net Cash Flow stood at $201.0 million in 2021, then spiked by 113.93% to $430.0 million in 2022, then soared by 111.40% to $909.0 million in 2023, then crashed by 88.67% to $103.0 million in 2024, then plummeted by 94.69% to $51.0 million in 2025.
- Its Net Cash Flow was $51.0 million in Q3 2025, compared to $469.0 million in Q2 2025 and -$1.6 billion in Q1 2025.